Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

One diagnosis every 8 minutes: Macmillan reports record UK prostate cancer rates

Macmillan Cancer Support reveals UK prostate cancer cases have reached 600,000, warning that common myths are preventing early detection.

One diagnosis every 8 minutes: Macmillan reports record UK prostate cancer rates

Each year in the UK, more than 68,000 men are diagnosed with prostate cancer, amounting to one new diagnosis every eight minutes, according to Macmillan Cancer Support. Since 2020, the number of men living with the disease has increased by 100,000, with the charity estimating there are now around 600,000 men in the UK with prostate cancer.

This represents the most common type of cancer diagnosed in the country. Dr Anthony Cunliffe, Macmillan Cancer Support's lead medical adviser, cautioned that misconceptions about prostate cancer could deter men from seeking medical attention. Many people mistakenly believe that feeling well automatically rules out the possibility of prostate cancer.

However, in its early stages, the disease may not present any symptoms, making regular check-ups with a GP crucial. Symptoms typically arise when the cancerous growth is large enough to put pressure on the urethra, the tube that transports urine. Although prostate cancer generally affects men over 50, it can also develop earlier in certain demographics, such as black men and those with a family history of the disease.

In recent years, the UK National Screening Committee has advised against routine prostate cancer screening for all men due to the potential for more harm than benefit. Nevertheless, the committee recommended screening for a select few thousand high-risk men carrying a specific gene mutation. In response to these findings, officials are planning to expand a screening trial, making it available to all eligible black men.

Cunliffe emphasized that the growing prevalence of prostate cancer can largely be attributed to an aging and expanding population.

Written by urgent.news from MyJoyOnline Ghana's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at 3news.com →

More in Health & Medicine

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Because intismeran autogene is a personalized cancer therapy made for each patient based on the individual genetic mutations of their tumors, the Merck-Moderna stock surge extended to sequencing…

  • Merck & Moderna's cancer vaccine shows positive Phase III results
  • Neoantigen therapy intismeran autogene improves RFS and DMFS
  • Illumina, PacBio, and Oxford Nanopore stocks surge 16%, 18%, and 39%

More from Sunday 23 August →